CLOs on the Move

Rubius Therapeutics

www.rubiustx.com

 
Rubius Therapeutics is a biopharmaceutical company pioneering a new era of cellular medicines. Our proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Our initial focus is to advance RCT™ product candidates for the treatment cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. We are currently enrolling patients in a Phase 1/2 clinical trial of RTX-240; the trial has two Phase 1 arms enrolling adult patients with ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.rubiustx.com
  • 399 Binney Street Suite 300
    Cambridge, MA USA 02139
  • Phone: 617.679.9600

Executives

Name Title Contact Details
Maiken Keson-Brookes
Chief Legal Officer and Corporate Secretary Profile
Maiken Keson-Brookes
Chief Legal Officer and Corporate Secretary Profile

Similar Companies

Bonna-Agela Technologies

Bonna-Agela Technologies is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

FIRSTMED HOLDING CORP

FIRSTMED HOLDING CORP is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Sensorion

Sensorion is a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, a study of SENS-401 in patients scheduled for cochlear implantation. Sensorion has entered into a broad strategic collaboration with Institut Pasteur focused on the genetics of hearing. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness including OTOF-GT, targeting deafness caused by a mutation of the gene encoding for otoferlin, and hearing loss related to mutation in GJB2 gene to potentially address important hearing loss segments in adults and children (GJB2-GT).

Stemline Therapeutics

Stemline Therapeutics is a clinical stage biopharmaceutical company developing oncology compounds that target cancer stem cells.

Cambria Biosciences

Cambria Biosciences is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.